
Amylyx Pharmaceuticals Investor Relations Material
Latest events

Q1 2025
Amylyx Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Amylyx Pharmaceuticals Inc
Access all reports
Amylyx Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company's research and product development primarily target conditions such as amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders, aiming to slow disease progression and improve patient outcomes. Amylyx leverages its scientific expertise in neurobiology to create therapies that address the underlying mechanisms of these diseases. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Key slides for Amylyx Pharmaceuticals Inc


Investor Presentation
Amylyx Pharmaceuticals Inc


M&A Announcement
Amylyx Pharmaceuticals Inc
Latest articles
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
Ticker symbol
AMLX
Country
🇺🇸 United States